What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.

The fortunes of RLY-2608 reverse, and a pivotal study will follow.

Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.

Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.

The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.

The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.